Alligator Bioscience AB (STO:ATORX) announced on Wednesday that it has regained exclusive, worldwide rights from Janssen Biotech Inc to develop and commercialise the CD40 agonistic antibody
, ADC-1013 (JNJ-64457107), its lead tumour-directed immunotherapy candidate, in phase I development for the treatment of metastatic cancer.
NORDIC BUSINESS REPORT-August 1, 2019-Alligator Bioscience regains from Janssen global rights to CD40 agonistic antibody
Additionally, in light of its ongoing strategic process, the Company continues to prudently advance its preclinical immuno-oncology pipeline: MM-401, an agonistic antibody
targeting a novel immuno-oncology target, TNFR2; and MM-201, a highly stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
These programs target immune stimulation, immune checkpoint inhibition, and regulatory T cell function and include: ASP8374/PTZ-201, an anti-TIGIT antibody and ASP1948/PTZ-329, an antiNRP1 antibody, both of which are currently in Phase I studies; and ASP1951/PTZ-522, a novel format GITR agonistic antibody
, which has achieved IND clearance.
To test whether 4-1BB plays a role in the increased skeletal muscle inflammation in the obese mice, we prepared primary muscle cells from mice and stimulated them with an anti-4-1BB agonistic antibody
. The absence of 4-1BB in primary muscle cells derived from 4-1BB-deficient (KO) mice was confirmed by RT-PCR analysis (Figure 3(a)).
A typical example of an agonistic antibody
causing disease is Graves' disease, in which the thyroid stimulating autoantibodies can activate the thyrotropin receptor .